• 1
    Powrie F. T cells in inflammatory bowel disease: protective and pathogenetic roles. Immunity 1995; 3: 158795.
  • 2
    Satsangi J, Parkes M, Louis E, et al. Two-stage genome-wide search in inflammatory bowel disease: evidence for susceptibility loci on chromosomes 3, 7, and 12. Nat Genet 1996; 14: 199202.
  • 3
    Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 24966.
  • 4
    Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn’s Disease Study’s results of drug treatment. Gastroenterology 1979; 77: 84769.
  • 5
    Reinisch W, Gasché C, Wyatt J, et al. Steroid dependency in Crohn’s disease. Lancet 1995; 345: 859859(Letter).
  • 6
    Korelitz BI, Adler DJ, Mendelsohn RA, et al. Long-term experience with 6-mercaptopurine in the treatment of Crohn’s disease. Am J Gastroenterol 1993; 8: 1198205.
  • 7
    Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn’s disease: a meta-analysis. Ann Int Med 1995; 122: 13242.
  • 8
    Feagan B, Rocon J, Fedorak R, et al. Methotrexate for the treatment of Crohn’s disease. N Eng J Med 1995; 332: 2927.
  • 9
    Targan SR, Van Hanauer SB, Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med 1997; 337: 102935.
  • 10
    Knobler RM, Trautinger F, Graninger W, et al. Parenteral administration of 8-methoxypsoralen in photopheresis. J Am Acad Dermatol 1993; 28: 5804.
  • 11
    Perez M, Edelson R, Laroche L, et al. Inhibition of antiskin allograft immunity by infusion with syngeneic photoinactivated effector lymphocytes. J Invest Dermatol 1989; 92: 66972.
  • 12
    Berger CL, Perez M, Laroche L, et al. Inhibition of autoimmune disease in a murine model of systemic lupus erythematosus induced by exposure to syngeneic photoinactivated lymphocytes. J Invest Dermatol 1990; 94: 527.
  • 13
    Girardi M, Herreid P, Tigelaar RE. Specific suppression of lupus-like graft-versus-host disease using extracorporeal photochemical attenuation of effector lymphocytes. J Invest Dermatol 1995; 104: 17782.
  • 14
    Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results. N Engl J Med 1987; 316: 297303.
  • 15
    Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098104.
  • 16
    Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. N Engl J Med 1998; 339: 174451.
  • 17
    Sunder-Plassmann G, Druml W, Steininger R, et al. Renal allograft rejection controlled by photopheresis. Lancet 1995; 346: 506506(Letter).
  • 18
    Rook AH, Jegasothy BV, Heald P, et al. Extracorporeal photochemotherapy for drug-resistant Pemphigus vulgaris. Ann Int Med 1990; 112: 3034.
  • 19
    Knobler RM, Graninger W, Lindmaier A, et al. Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. Arthritis Rheum 1992; 35: 31924.
  • 20
    Rook AH, Freundlich B, Jegasothy BV, et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy: results of a multicenter trial. Arch Dermatol 1992; 128: 33746.
  • 21
    Becherel PA, Bussel A, Chosidow O, et al. Extracorporeal photochemotherapy for chronic erosive Lichen planus. Lancet 1998; 351: 805805(Letter).
  • 22
    Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index—National Crohn’s Disease Study. Gastroenterology 1976; 70: 43944.
  • 23
    Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994; 106: 28796.
  • 24
    Gerber M, Gmeinhart B, Volc-Platzer B, et al. Complete remission of lichen-planus-like graft-versus-host disease (GvHD) with extracorporal photochemotherapy(ECP). Bone Marrow Transp 1997; 19: 5179.
  • 25
    Wyatt J, Vogelsang H, Hübl W, et al. Intestinal permeability and the prediction of relapse in Crohn’s disease. Lancet 1993; 341: 14379.
  • 26
    Yang X-Y, Gasparro FP, DeLeo VA, et al. 8-Methoxypsoralen-DNA adducts in patients treated with 8-methoxypsoralen and ultraviolet A light. J Invest Dermatol 1989; 92: 5963.
  • 27
    Greinix HT, Volc-Platzer B, Kalhs P, et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000; 96: 242631.
  • 28
    Lerebours E, Bussel A, Modigliani R, et al. Treatment of Crohn’s disease by lymphocyte apheresis: a randomized controlled trial. Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1994; 107: 35761.
  • 29
    Aringer M, Graninger WB, Smolen JS, et al. Photopheresis treatment enhances CD95 (Fas) expression in circulating lymphocytes of patients with systemic sclerosis and induces apoptosis. Br J Rheumatol 1997; 36: 127682.
  • 30
    Yoo EK, Rook AH, Elenitsas R, et al. Apoptosis induction by ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: Relevance to mechanism of therapeutic action. J Invest Dermatol 1996; 107: 23542.
  • 31
    Klosner G, Trautinger F, Knobler R, et al. Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen plus ultraviolet A radiation induces a shift in cytokine expression from a Th1 to a Th2 response. J Invest Dermatol 2001; 116: 45962.DOI: 10.1046/j.1523-1747.2001.01276.x